FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165338002> ?p ?o ?g. }

• W2165338002 endingPage "1286" @default.
• W2165338002 startingPage "1278" @default.
• W2165338002 abstract "BackgroundCo-trimoxazole prophylaxis can reduce mortality from untreated HIV infection in Africa; whether benefits occur alongside combination antiretroviral therapy (ART) is unclear. We estimated the effect of prophylaxis after ART initiation in adults.MethodsParticipants in our observational analysis were from the DART randomised trial of management strategies in HIV-infected, symptomatic, previously untreated African adults starting triple-drug ART with CD4 counts lower than 200 cells per μL. Co-trimoxazole prophylaxis was not routinely used or randomly allocated, but was variably prescribed by clinicians. We estimated effects on clinical outcomes, CD4 cell count, and body-mass index (BMI) using marginal structural models to adjust for time-dependent confounding by indication. DART was registered, number ISRCTN13968779.Findings3179 participants contributed 14 214 years of follow-up (8128 [57%] person-years on co-trimoxazole). Time-dependent predictors of co-trimoxazole use were current CD4 cell count, haemoglobin concentration, BMI, and previous WHO stage 3 or 4 events on ART. Present prophylaxis significantly reduced mortality (odds ratio 0·65, 95% CI 0·50–0·85; p=0·001). Mortality risk reduction on ART was substantial to 12 weeks (0·41, 0·27–0·65), sustained from 12–72 weeks (0·56, 0·37–0·86), but not evident subsequently (0·96, 0·63–1·45; heterogeneity p=0·02). Variation in mortality reduction was not accounted for by time on co-trimoxazole or current CD4 cell count. Prophylaxis reduced frequency of malaria (0·74, 0·63–0·88; p=0·0005), an effect that was maintained with time, but we observed no effect on new WHO stage 4 events (0·86, 0·69–1·07; p=0·17), CD4 cell count (difference vs non-users, −3 cells per μL [−12 to 6]; p=0·50), or BMI (difference vs non-users, −0·04 kg/m2 [−0·20 to 0·13); p=0·68].InterpretationOur results reinforce WHO guidelines and provide strong motivation for provision of co-trimoxazole prophylaxis for at least 72 weeks for all adults starting combination ART in Africa.FundingUK Medical Research Council, the UK Department for International Development, the Rockefeller Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories." @default.
• W2165338002 created "2016-06-24" @default.
• W2165338002 creator A5005633222 @default.
• W2165338002 creator A5006641773 @default.
• W2165338002 creator A5010243991 @default.
• W2165338002 creator A5015958019 @default.
• W2165338002 creator A5022635990 @default.
• W2165338002 creator A5028823785 @default.
• W2165338002 creator A5030902925 @default.
• W2165338002 creator A5043684973 @default.
• W2165338002 creator A5044248283 @default.
• W2165338002 creator A5044933203 @default.
• W2165338002 creator A5053442063 @default.
• W2165338002 creator A5068494724 @default.
• W2165338002 creator A5090095722 @default.
• W2165338002 date "2010-04-01" @default.
• W2165338002 modified "2023-10-12" @default.
• W2165338002 title "Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort" @default.
• W2165338002 cites W1665589980 @default.
• W2165338002 cites W1997844567 @default.
• W2165338002 cites W1999408007 @default.
• W2165338002 cites W1999500342 @default.
• W2165338002 cites W2003597130 @default.
• W2165338002 cites W2009187570 @default.
• W2165338002 cites W2016127823 @default.
• W2165338002 cites W2026219980 @default.
• W2165338002 cites W2041776821 @default.
• W2165338002 cites W2054219948 @default.
• W2165338002 cites W2060831367 @default.
• W2165338002 cites W2090740440 @default.
• W2165338002 cites W2093788811 @default.
• W2165338002 cites W2097239572 @default.
• W2165338002 cites W2122483069 @default.
• W2165338002 cites W2125404477 @default.
• W2165338002 cites W2129994024 @default.
• W2165338002 cites W2130060580 @default.
• W2165338002 cites W2130603879 @default.
• W2165338002 cites W2132136467 @default.
• W2165338002 cites W2153189426 @default.
• W2165338002 cites W2159324987 @default.
• W2165338002 cites W2162881343 @default.
• W2165338002 cites W2163477848 @default.
• W2165338002 cites W2165010366 @default.
• W2165338002 cites W2187955543 @default.
• W2165338002 cites W2331414045 @default.
• W2165338002 cites W2337061131 @default.
• W2165338002 doi "https://doi.org/10.1016/s0140-6736(10)60057-8" @default.
• W2165338002 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2858802" @default.
• W2165338002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20347483" @default.
• W2165338002 hasPublicationYear "2010" @default.
• W2165338002 type Work @default.
• W2165338002 sameAs 2165338002 @default.
• W2165338002 citedByCount "114" @default.
• W2165338002 countsByYear W21653380022012 @default.
• W2165338002 countsByYear W21653380022013 @default.
• W2165338002 countsByYear W21653380022014 @default.
• W2165338002 countsByYear W21653380022015 @default.
• W2165338002 countsByYear W21653380022016 @default.
• W2165338002 countsByYear W21653380022017 @default.
• W2165338002 countsByYear W21653380022018 @default.
• W2165338002 countsByYear W21653380022019 @default.
• W2165338002 countsByYear W21653380022020 @default.
• W2165338002 countsByYear W21653380022021 @default.
• W2165338002 countsByYear W21653380022022 @default.
• W2165338002 countsByYear W21653380022023 @default.
• W2165338002 crossrefType "journal-article" @default.
• W2165338002 hasAuthorship W2165338002A5005633222 @default.
• W2165338002 hasAuthorship W2165338002A5006641773 @default.
• W2165338002 hasAuthorship W2165338002A5010243991 @default.
• W2165338002 hasAuthorship W2165338002A5015958019 @default.
• W2165338002 hasAuthorship W2165338002A5022635990 @default.
• W2165338002 hasAuthorship W2165338002A5028823785 @default.
• W2165338002 hasAuthorship W2165338002A5030902925 @default.
• W2165338002 hasAuthorship W2165338002A5043684973 @default.
• W2165338002 hasAuthorship W2165338002A5044248283 @default.
• W2165338002 hasAuthorship W2165338002A5044933203 @default.
• W2165338002 hasAuthorship W2165338002A5053442063 @default.
• W2165338002 hasAuthorship W2165338002A5068494724 @default.
• W2165338002 hasAuthorship W2165338002A5090095722 @default.
• W2165338002 hasBestOaLocation W21653380022 @default.
• W2165338002 hasConcept C126322002 @default.
• W2165338002 hasConcept C142462285 @default.
• W2165338002 hasConcept C156957248 @default.
• W2165338002 hasConcept C187212893 @default.
• W2165338002 hasConcept C201903717 @default.
• W2165338002 hasConcept C203014093 @default.
• W2165338002 hasConcept C23131810 @default.
• W2165338002 hasConcept C2776939746 @default.
• W2165338002 hasConcept C2776983459 @default.
• W2165338002 hasConcept C2779496540 @default.
• W2165338002 hasConcept C2780221984 @default.
• W2165338002 hasConcept C2993143319 @default.
• W2165338002 hasConcept C3013748606 @default.
• W2165338002 hasConcept C71924100 @default.
• W2165338002 hasConcept C72563966 @default.
• W2165338002 hasConcept C77350462 @default.
• W2165338002 hasConceptScore W2165338002C126322002 @default.
• W2165338002 hasConceptScore W2165338002C142462285 @default.

• next